Phase 2Completed

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105

Sponsor
Gradalis, Inc. (Industry)
Enrollment
5 enrolled
Conditions
Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Interventions
Vigil™ Vaccine; Bevacizumab
Ages
adults, older adults
Registry
NCT01551745

Full record on ClinicalTrials.gov

From the registry

This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.

Primary outcomes

  • Time to Progression
  • Response Rate

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered